Healthcare: A Surprising Reversal for Alkermes, Celldex's Super Bad News, and J&J's Q1 in Review

<p>Alkermes’ ALKS-5461 gets a do-over, Celldex's lead drug is a bust, and the good and bad of Johnson & Johnson's Q1 earnings report. </p> <p>Thanks to Blooom for supporting Industry Focus. Get a month free with <strong>blooom401k.com/fool and code fool</strong>.</p>